


For personal use only



# Half-Year Financial Report

December 2024



## 1. Company details

Name of entity:	Cryosite Limited
ABN:	86 090 919 476
Reporting period:	For the half-year ended 31 December 2024
Previous period:	For the half-year ended 31 December 2023
Reporting Currency:	Australian Dollars

## 2. Results for announcement to the market

	31 Dec 2024 \$'000	31 Dec 2023 \$'000	Change \$'000	Change %
Revenue from ordinary activities	6,640	6,402	238	4%
Profit before tax for the period from ordinary activities	1,118	961	157	16%
Profit (loss) from ordinary activities after tax attributable to members	838	846	(8)	(1%)

### Dividends

On 20 August 2024 the Board of Cryosite Limited declared an unfranked dividend of 2 cents per share which was paid to shareholders on the 10 October 2024, for the financial year ending 30 June 2024. This compares with a 1.5 cent unfranked final dividend, paid to shareholders, during the half-year ending 31 December 2023 (for the financial year ending 30 June 2023).

The profit for the Group after providing for income tax amounted to \$838,000 (31 December 2023: \$846,000).

### Commentary on the results to the market

Results for half-year ending 31 December 2024 reflect a strengthening of trading conditions.

- Gross profit of \$4,251,000, up 7.5%.
- Earnings before interest, tax, depreciation and amortisation (**EBITDA**) of \$1,518,000, up 15%.
- Earnings before interest and tax (**EBIT**) of \$1,107,000, up 19%.
- 2 cents per share unfranked final dividend paid on 10 October 2024, for the financial year ending 30 June 2024 up 33%.
- The Group had carried-forward tax credits to offset income tax expenses in the prior period, but nil for the current period.
- No bank borrowings.

A further explanation of the result of the current period is set out in the Directors' Report contained in the attached audit reviewed Interim Report.

## 3. Net tangible assets backing

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	3.15	6.20

The calculation of net tangible assets excludes right-of-use assets, intangible assets, and lease liabilities.

The key driver of the reduction of net tangible assets backing was due to the Group making an equal share reduction of 5c per share (\$2.4m) in February 2024.

#### 4. Dividends

##### *Current period*

	Amount per security Cents	Franked amount per security Cents
Final unfranked dividend paid during the half-year ended 31 December 2024	2.00	-

##### *Previous period*

	Amount per security Cents	Franked amount per security Cents
Final unfranked dividend paid during the half-year ended 31 December 2023	1.50	-

#### 5. Audit qualification or review

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

#### 6. Attachments

The Interim Report of Cryosite Limited for the half-year ended 31 December 2024 is attached.

#### 7. Signed

Signed Mark Kerr  
Mark Kerr  
Non-Executive Chairman

Date: 20 February 2025

**Cryosite Limited**

**ABN 86 090 919 476**

**Interim Report - 31 December 2024**

Directors' report	2
Auditor's independence declaration	7
Consolidated statement of profit or loss and other comprehensive income	8
Consolidated statement of financial position	9
Consolidated statement of changes in equity	10
Consolidated statement of cash flows	11
Notes to the consolidated financial statements	12
Directors' declaration	23
Independent auditor's report to the members of Cryosite Limited	24

For personal use only

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of Cryosite Limited (referred to hereafter as 'Cryosite', the 'Company' or 'parent entity') and the entity it controlled at the end of, or during, the half-year ended 31 December 2024.

## Directors

The following persons were directors of Cryosite Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Mark Kerr	Non-Executive Chairman
Andrew Kerr	Executive Director (Non-Executive Director up to 19 August 2024; appointed as Executive Director on 20 August 2024)
Scott Thomas	Non-Executive Director

## Dividends

Dividends paid during the financial half-year were as follows:

	31 Dec 2024	31 Dec 2023
	\$'000	\$'000
Final unfranked dividend paid during the half-year for the year ended 30 June 2024 of 2.0 cents (30 June 2023: 1.5 cents) per ordinary share.	976	732

## Principal activities

During the financial half-year the principal activities of the Group consisted of:

- Clinical trials and biological services logistics:** Specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns, biological services and cell gene therapies depot services.
- Cord Blood and tissue storage:** Storage of cord blood and tissue samples.

## Review of operations

The profit for the Group after providing for income tax amounted to \$838,000, including a tax provision of \$280,000 (31 December 2023: \$846,000 including a tax provision of \$115,000).

## Earnings per share

	31 Dec 2024	31 Dec 2023
	Cents	Cents
Basic earnings per share	1.72	1.73
Diluted earnings per share	1.72	1.73

## Overview

The Directors are delighted to advise that the financial results for the half-year ended 31 December 2024, overall, exceeded the previous financial result for the half-year ended 31 Dec 2023 (prior corresponding period) in terms of Revenue, Operating Profit, EBIT and EBITDA, continuing to build upon our long-term strategy and year-on-year positive momentum at Cryosite.

The Group reported revenue from ordinary activities of \$6,640,000 (31 December 2023: \$6,402,000) and delivered net profit after tax of \$838,000 (31 December 2023: \$846,000) for the first half of the 2025 financial year.


The Directors consider Earnings Before Interest and Tax ('EBIT') and Earnings Before Interest, Tax, Depreciation and Amortisation ('EBITDA') to reflect the core earnings of the Group. EBIT and EBITDA are financial measures which are not prescribed by Australian Accounting Standards ('AAS') and represent the profit under AAS adjusted for non-cash and significant items. The Group's reconciliation of its statutory net profit after tax ('NPAT') for the current and previous year to EBIT and EBITDA is as follows:

	31 Dec 2024 \$'000	31 Dec 2023 \$'000	Change \$'000	Change %
<b>Reported financials</b>				
<b>Revenue</b>	6,640	6,402	238	4%
Cost of providing services	(2,389)	(2,447)	58	(2%)
<b>Gross profit</b>	4,251	3,955	296	7%
<b>Net profit after tax</b>	838	846	(8)	(1%)
Add: Income tax expense	280	115	165	143%
Add: Interest expenses	77	83	(6)	(7%)
Less: Interest revenue calculated using effective interest method	(88)	(110)	22	(20%)
<b>EBIT</b>	1,107	934	173	19%
Add: Depreciation and amortisation expense	411	391	20	5%
<b>EBITDA</b>	1,518	1,325	193	15%

It is particularly pleasing to report a 19% increase in EBIT and a 15% increase in EBITDA in the first-half of 2025. The Group achieved strong operational efficiencies by tightly controlling costs while purposefully investing in our facilities, systems and staff, to optimally position the Group for continued growth.

- Revenue from ordinary activities increased by 4% to \$6,640,000 in the current period from \$6,402,000 in the prior corresponding period. It is particularly pleasing to note strong momentum in the revenue from inbound, storage, and outbound activities that present the highest margin opportunity for Cryosite.
- Gross profit increased by 7% to \$4,251,000 as costs were tightly controlled in the period.
- EBIT increased by 19% to \$1,107,000.
- EBITDA increased by 15% to \$1,518,000 demonstrating the low incremental cost of scaling our business in the immediate future.
- NPAT decreased by 1% to \$838,000 driven by an increase in the Group's income tax expense (up \$165,000 on the prior corresponding period) as there were no carried-forward tax credits remaining in the period.

The graph below demonstrates the expanding revenue and EBITDA growth profile of Cryosite against prior comparable periods:



The Board declared a final unfranked dividend of 2.0 cents per share for FY2024, a 33% increase from FY2023 (1.5 cent per share).

In addition, the Group returned 5c per share (\$2.4m) to shareholders in February 2024 via a capital reduction.

During the first half of FY2025, the Group undertook a major capital works project and increased the footprint of its existing facility by 17%. The project was fully completed in February 2025. This will allow Cryosite to double the number of freezers and liquid nitrogen tanks on site.

On 15 January 2025, the Group launched a new and interactive Investor Hub for dedicated investor engagement. The Investor Hub enables Cryosite's shareholders, stakeholders and prospective investors to learn more about the entity's activities and communicate with the Group's leadership team directly.

The Directors are extremely pleased with the positive momentum demonstrated in our half-year December 2024 results. Cryosite is poised for further growth in 2025 as we build upon the investments made to date in our people, processes and facility.

The Board would like to thank the Cryosite staff for their outstanding performance and shareholders for their ongoing trust and support.

#### **Cashflow**

The Group has no debt facilities and continues to hold \$4,487,000 cash on hand as at 31 December 2024 compared to \$4,703,000 cash on hand as at 30 June 2024. The material drivers for the change in cashflow are itemised below:

- **Cash balance – 30 June 2024: \$4,703,000**
  - **Net cash inflow from operations: \$1,140,000** (1HY24: \$1,219,000)
    - Small timing differences of receivables/payables compared to 1HY24.
  - **Net cash outflow from investing activities: (\$225,000)** (1HY24: \$859,000)
    - Interest income received: \$79,000 (1HY24: \$55,000).
    - Capital expenditure on mezzanine extension: (\$305,000) (1HY24: (\$196,000))
    - Note: A \$1m long-term deposit was reclassified as cash from non-current assets in 1HY24 (no such adjustment occurred in this period).
  - **Net cash outflow from financing activities: (\$1,131,000)** (1HY24: (\$882,000))
    - Dividend payment of 2c per share – October 2024: (\$976,000) (1HY24: (\$732,000))
    - Facility lease expenses: (\$155,000) (1HY24: (\$150,000)).
- **Cash balance – 31 December 2024: \$4,487,000**

#### **Environmental, social and governance (ESG)**

Our facility improvements reflect decisions to improve the design, construction, and operations of the facility to reduce our environmental impact. Past and current investments in new capital equipment contributes to our GHG reduction strategy. Our unwavering commitment to sustainability has resulted in our recent achievement of a silver medal from EcoVadis in February 2024. Our updated Governance Policies reflect our commitment to ethical, transparent, and responsible business practices.

We are committed to reducing GHG emissions in line with climate science targeting net zero by 2050. Our objective is to understand, manage, and reduce our greenhouse gas emissions across all operational activities. Our Scope 1 and Scope 2 greenhouse gas emissions for the calendar year 2024 was 445 tonnes (Est.) of carbon dioxide equivalent (CO<sub>2</sub>e). We continue to investigate and refine our reporting of Scope 3 emissions in line with our commitment to our GHG reduction strategy.

#### **Stability in the state of affairs**

Our stability in a changing industry landscape reflects effective strategic planning and execution. It highlights our ability to maintain a steady course while adapting to the evolving needs of our clients and the market.

### *Governance and Management*

In Governance and Management, our Board steadfastly upholds the highest standards of corporate governance and ethical behaviour. We continue to enhance our ESG policies, integrating our GHG reduction strategy to our environmental guidelines. These updates are designed to align with and reinforce our Group's strategic objectives with our customers and stakeholders, while enhancing transparency and accountability at all levels.

Further demonstrating our commitment to continuous improvement, we actively engage in external assessments through the EcoVadis platform. These assessments not only provide valuable insights but also serve as a crucial benchmark against industry standards, guiding our ongoing efforts to elevate our operational practices and ethical standards.

### *Material business risks*

We remain vigilant in the face of macroeconomic risks, climate change and regulatory compliance challenges. We continue to update and invest in the latest technology and equipment to manage and monitor the impact of the climate on our operations. Our diverse customer base and strategic partnerships are key in helping us manage these risks.

#### *Macroeconomic*

Despite our strong position in the specialist clinical trials storage and logistics sector, we recognise that we are not immune to external economic factors such as inflation, supply chain disruptions and new competitors. Our strategy involves monitoring economic indicators, maintaining strict internal controls, and diversifying our customer base into the new growth sectors such as biological storage and cell & gene therapies storage and depot services leveraging our 23 years of cryogenic cord blood expertise.

#### *Regulatory compliance*

The Group's purpose-built, modern facility is licensed by the Therapeutic Goods Administration (TGA) of Australia and is Good Manufacturing Practice (GMP) certified to support the specialised needs of highly regulated, temperature-sensitive products. We take our quality obligations and responsibilities seriously. Cryosite maintains accreditations, has thorough knowledge of regulatory systems and utilises best-in-class management systems to ensure our quality processes.

Cryosite employs regular and extensive audits to mitigate our risk and ensure our storage facilities meet TGA and our customers' standards. Additionally, the Group maintains sufficient internal controls to ensure continued compliance with its regulatory obligations as well as all Australian laws and regulations.

#### *Privacy and cybersecurity*

In an era where data security is paramount, the Group has continuously invested in staff training and infrastructure to protect sensitive information and maintain cybersecurity. Cryosite has initiated its journey to align with the Australian Signals Directorate (ASD) Essential Eight Maturity Model.

#### *Work, health and safety ('WHS')*

The Group has a zero-risk tolerance for serious safety incidents. The Group deploys a continuous improvement process to its WHS practices, emphasising its established safety culture throughout the organisation, and providing scheduled training for the workforce.

#### *Operating risks*

- **Supply Chain disruption.** The Group is part of a global supply chain facilitating the conduct of clinical trials in Australia. Disruption to this supply chain, as we saw during Covid, brings both challenges and opportunities requiring the Group to remain agile in its response.
- **Commercial Partners:** The Group is aware of the importance of global pharmaceutical and bio-tech companies within its Clinical Trials division and mitigates risk through consistently high levels of customer service, the attraction of new clients, and expansion of its licenses and services.
- **Competition:** The Group is vigilant regarding the possibility of a new market entrant or a change in the delivery model for Clinical Trials in Australia. It mitigates this risk by holding a number of licenses and certifications, investing in its facilities, services and people and by remaining closely connected to its customers. The Group continually invests in its brand and enjoys a high reputation in Australia and internationally.

**Significant changes in the state of affairs**

There were no significant changes in the state of affairs of the Group during the financial half-year.

**Rounding of amounts**

The Group is of a kind referred to in Corporations Instrument 2016/191, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest thousand dollars, or in certain cases, the nearest dollar.

**Auditor's independence declaration**

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors

A handwritten signature in black ink that reads "Mark Kerr".

Mark Kerr  
Non-Executive Chairman

20 February 2025

## Auditor's Independence Declaration to the Directors of Cryosite Limited

In relation to our review of the financial report of Cryosite Limited and its controlled entity for the half-year ended 31 December 2024 to the best of my knowledge and belief, there have been:

- no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Cryosite Limited and its controlled entity during the half-year ended 31 December 2024.

**Forvis Mazars**

Forvis Mazars Audit & Assurance Pty Ltd

**A. Aupied**

Alexis Aupied

Director

20 February 2025

**Cryosite Limited**  
**Consolidated statement of profit or loss and other comprehensive income**  
**For the half-year ended 31 December 2024**



		<b>Consolidated</b>	
	<b>Note</b>	<b>31 Dec 2024 \$'000</b>	<b>31 Dec 2023 \$'000</b>
<b>Revenue</b>	4	6,640	6,402
<b>Expenses</b>			
Administration expenses	5	(2,379)	(2,283)
Cost of providing services		(2,389)	(2,447)
Depreciation and amortisation expense	5	(411)	(391)
Marketing expenses		(24)	(16)
Occupancy expenses		(330)	(331)
Total expenses		<u>(5,533)</u>	<u>(5,468)</u>
<b>Operating profit</b>		1,107	934
Interest revenue calculated using the effective interest method		88	110
Finance costs	5	<u>(77)</u>	<u>(83)</u>
<b>Profit before income tax expense</b>		1,118	961
Income tax expense	6	<u>(280)</u>	<u>(115)</u>
<b>Profit after income tax expense for the half-year attributable to the owners of Cryosite Limited</b>		838	846
Other comprehensive income for the half-year, net of tax		<u>-</u>	<u>-</u>
<b>Total comprehensive income for the half-year attributable to the owners of Cryosite Limited</b>		<u><u>838</u></u>	<u><u>846</u></u>
		<b>Cents</b>	<b>Cents</b>
Basic earnings per share	7	1.72	1.73
Diluted earnings per share	7	1.72	1.73

*The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes*

		<b>Consolidated</b>	
	<b>Note</b>	<b>31 Dec 2024 \$'000</b>	<b>30 Jun 2024 \$'000</b>
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents	8	4,487	4,703
Trade and other receivables	9	1,845	1,406
Inventories - stock on hand		56	59
Customer acquisition and fulfilment costs	10	1,082	1,126
Other assets		267	443
<b>Total current assets</b>		<u>7,737</u>	<u>7,737</u>
<b>Non-current assets</b>			
Property, plant and equipment	11	1,485	1,451
Right-of-use assets	12	2,129	2,259
Intangibles assets		2	4
Deferred tax assets		1,020	1,030
Customer acquisition and fulfilment costs	10	6,511	7,030
Other assets		201	202
<b>Total non-current assets</b>		<u>11,348</u>	<u>11,976</u>
<b>Total assets</b>		<u>19,085</u>	<u>19,713</u>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables		1,303	1,150
Contract liabilities		2,061	2,096
Lease liabilities		189	179
Provision for income tax		437	217
Employee benefits		284	284
Other liabilities	13	64	64
<b>Total current liabilities</b>		<u>4,338</u>	<u>3,990</u>
<b>Non-current liabilities</b>			
Trade and other payables		442	442
Contract liabilities		10,204	10,925
Lease liabilities		2,168	2,266
Employee benefits		118	137
Provisions		209	209
Other liabilities	13	295	295
<b>Total non-current liabilities</b>		<u>13,436</u>	<u>14,274</u>
<b>Total liabilities</b>		<u>17,774</u>	<u>18,264</u>
<b>Net assets</b>		<u>1,311</u>	<u>1,449</u>
<b>Equity</b>			
Issued capital	14	3,538	3,538
Accumulated losses		<u>(2,227)</u>	<u>(2,089)</u>
<b>Total equity</b>		<u>1,311</u>	<u>1,449</u>

*The above consolidated statement of financial position should be read in conjunction with the accompanying notes*

	<b>Consolidated</b>	<b>Issued capital \$'000</b>	<b>Accumulated losses \$'000</b>	<b>Total equity \$'000</b>
Balance at 1 July 2023		5,979	(3,197)	2,782
Profit after income tax expense for the half-year		-	846	846
Other comprehensive income for the half-year, net of tax		-	-	-
Total comprehensive income for the half-year		-	846	846
<i>Transactions with owners in their capacity as owners:</i>				
Dividends paid (note 15)		-	(732)	(732)
Balance at 31 December 2023		<u>5,979</u>	<u>(3,083)</u>	<u>2,896</u>
	<b>Consolidated</b>	<b>Issued capital \$'000</b>	<b>Accumulated losses \$'000</b>	<b>Total equity \$'000</b>
Balance at 1 July 2024		3,538	(2,089)	1,449
Profit after income tax expense for the half-year		-	838	838
Other comprehensive income for the half-year, net of tax		-	-	-
Total comprehensive income for the half-year		-	838	838
<i>Transactions with owners in their capacity as owners:</i>				
Dividends paid (note 15)		-	(976)	(976)
Balance at 31 December 2024		<u>3,538</u>	<u>(2,227)</u>	<u>1,311</u>

*The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes*

		<b>Consolidated</b>	<b>Consolidated</b>
	<b>Note</b>	<b>31 Dec 2024 \$'000</b>	<b>31 Dec 2023 \$'000</b>
<b>Cash flows from operating activities</b>			
Receipts from customers (inclusive of GST)		5,772	5,665
Payments to suppliers and employees (inclusive of GST)		(4,505)	(4,363)
Interest and other finance costs paid		(77)	(83)
Income taxes paid		(50)	-
Net cash from operating activities		1,140	1,219
<b>Cash flows from investing activities</b>			
Payments for property, plant and equipment	11	(305)	(196)
Investment of cash in short-term deposits		-	1,000
Interest received		80	55
Net cash (used in)/from investing activities		(225)	859
<b>Cash flows from financing activities</b>			
Dividends paid	15	(976)	(732)
Repayment of lease liabilities		(155)	(150)
Net cash used in financing activities		(1,131)	(882)
Net (decrease)/increase in cash and cash equivalents		(216)	1,196
Cash and cash equivalents at the beginning of the financial half-year		4,703	4,731
Cash and cash equivalents at the end of the financial half-year		4,487	5,927

*The above consolidated statement of cash flows should be read in conjunction with the accompanying notes*

## **Note 1. General information**

The financial statements cover Cryosite Limited as a Group consisting of Cryosite Limited and the entity it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is Cryosite Limited's functional and presentation currency.

Cryosite Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

13a Ferndell Street  
South Granville  
NSW 2142

A description of the nature of the Group's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 20 February 2025.

## **Note 2. Material accounting policies**

These general purpose financial statements for the interim half-year reporting period ended 31 December 2024 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the *Corporations Act 2001*, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2024 and any public announcements made by the Company during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

### **New or amended Accounting Standards and Interpretations adopted**

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the Group during the half-year ended 31 December 2024 and are not expected to have a significant impact for the full financial year ending 30 June 2025.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

### Note 3. Operating segments

#### Identification of reportable operating segments

The Group is organised into two operating segments: Clinical trials and biological services logistics and Cord blood and tissue storage. These operating segments are based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources. There is no aggregation of operating segments.

**Clinical trials and biological services logistics** Specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological services.

**Cord blood and tissue storage** Storage of cord blood and tissue samples.

The CODM review EBITDA (earnings before interest, tax, depreciation and amortisation). The accounting policies adopted for internal reporting to the CODM are consistent with those adopted in the financial statements.

The information reported to the CODM is on a monthly basis.

#### Major customers

The Group services a highly specialised and often concentrated market segment, of which during the half-year ended 31 December 2024, approximately 76% of the Group's external revenue was derived from sales to three major global clients.

#### Operating segment information

	Clinical trials and biological services logistics \$'000	Cord blood and tissue storage \$'000	Corporate \$'000	Total \$'000
<b>Consolidated - 31 Dec 2024</b>				
<b>Revenue</b>				
Sales to external customers	5,477	1,163	-	6,640
<b>Total revenue</b>	<u>5,477</u>	<u>1,163</u>	<u>-</u>	<u>6,640</u>
<b>EBITDA</b>	2,690	342	(1,514)	1,518
Depreciation and amortisation expense	(349)	(14)	(48)	(411)
Interest revenue	-	-	88	88
Finance costs	(55)	(6)	(16)	(77)
<b>Profit/(loss) before income tax expense</b>	<u>2,286</u>	<u>322</u>	<u>(1,490)</u>	<u>1,118</u>
Income tax expense				(280)
<b>Profit after income tax expense</b>				<u>838</u>
<b>Assets</b>				
Segment assets	3,215	8,610	7,260	19,085
<b>Total assets</b>				<u>19,085</u>
<b>Liabilities</b>				
Segment liabilities	1,055	12,662	4,057	17,774
<b>Total liabilities</b>				<u>17,774</u>

**Note 3. Operating segments (continued)**

	Clinical trials and biological services logistics \$'000	Cord blood and tissue storage \$'000	Corporate \$'000	Total \$'000
<b>Consolidated - 31 Dec 2023</b>				
<b>Revenue</b>				
Sales to external customers	5,276	1,126	-	6,402
<b>Total revenue</b>	<b>5,276</b>	<b>1,126</b>	<b>-</b>	<b>6,402</b>
<b>EBITDA</b>	2,361	287	(1,323)	1,325
Depreciation and amortisation expense	(331)	(13)	(47)	(391)
Interest revenue	-	-	110	110
Finance costs	(59)	(6)	(18)	(83)
<b>Profit/(loss) before income tax expense</b>	<b>1,971</b>	<b>268</b>	<b>(1,278)</b>	<b>961</b>
Income tax expense				(115)
<b>Profit after income tax expense</b>				<b>846</b>
<b>Consolidated - 30 Jun 2024</b>				
<b>Assets</b>				
Segment assets	2,726	9,271	7,716	19,713
<b>Total assets</b>				<b>19,713</b>
<b>Liabilities</b>				
Segment liabilities	1,265	13,054	3,945	18,264
<b>Total liabilities</b>				<b>18,264</b>

*Geographical information*

The sales to external customers for both operating segments are from Australia.

**Note 4. Revenue**

	<b>Consolidated 31 Dec 2024 \$'000</b>	<b>31 Dec 2023 \$'000</b>
<i>Revenue from contracts with customers</i>		
Revenue from clinical trials, logistics and biological services	5,477	5,276
Revenue from cord blood and tissue storage (i)	1,163	1,126
<b>Revenue</b>	<b>6,640</b>	<b>6,402</b>
	<b>Consolidated 31 Dec 2024 \$'000</b>	<b>31 Dec 2023 \$'000</b>
<i>(i) Cord blood and tissue storage is comprised of:</i>		
Cord blood and tissue storage revenue	268	208
Cord blood historical contract revenue	895	918
<b>Total cord blood and tissue storage revenue</b>	<b>1,163</b>	<b>1,126</b>

**Note 4. Revenue (continued)**

	Consolidated 31 Dec 2024 \$'000	31 Dec 2023 \$'000
* Cord blood deferred revenues and costs are comprised of:		
Cord blood historical contract liabilities	895	918
Cord blood historical contract assets	(563)	(598)
Cord blood historical deferred income tax expense	(83)	(80)
Total cord blood historical deferred net income	<u>249</u>	<u>240</u>

\* Refer to note 3 'Operating segments'.

*Disaggregation of revenue*

The disaggregation of revenue from contracts with customers is as follows:

	Consolidated 31 Dec 2024 \$'000	31 Dec 2023 \$'000
<i>Geographical regions</i>		
Australia*	<u>6,640</u>	<u>6,402</u>
<i>Timing of revenue recognition</i>		
Goods transferred at a point in time	3,488	3,418
Services transferred over time	<u>3,152</u>	<u>2,984</u>
	<u>6,640</u>	<u>6,402</u>

\* The geographical regions are determined based on the place where the services occur.

**Note 5. Expenses**

	<b>Consolidated</b>	
	<b>31 Dec</b>	<b>31 Dec</b>
	<b>2024</b>	<b>2023</b>
	<b>\$'000</b>	<b>\$'000</b>
Profit before income tax includes the following specific expenses:		
<i>Depreciation and amortisation expense</i>		
Depreciation - Property plant and equipment	279	259
Depreciation - Right-of-use assets	130	130
Amortisation - Intangibles assets	2	2
	<hr/>	<hr/>
Total depreciation and amortisation	411	391
<i>Finance costs</i>		
Interest portion of monies owed to ACCC	11	12
Interest and finance charges paid/payable on lease liabilities	66	71
	<hr/>	<hr/>
Finance costs expensed	77	83
<i>Superannuation expense</i>		
Defined contribution superannuation expense	177	151
	<hr/>	<hr/>
<i>Employee benefits expense excluding superannuation</i>		
Employee benefits expense excluding superannuation	1,346	1,309
	<hr/>	<hr/>

**Note 6. Income tax**

	<b>Consolidated</b>	
	<b>31 Dec</b>	<b>31 Dec</b>
	<b>2024</b>	<b>2023</b>
	<b>\$'000</b>	<b>\$'000</b>
<i>Income tax expense</i>		
Current tax	270	164
Deferred tax - origination and reversal of temporary differences	10	(49)
	<hr/>	<hr/>
Aggregate income tax expense	280	115
<i>Numerical reconciliation of income tax expense and tax at the statutory rate</i>		
Profit before income tax expense	1,118	961
	<hr/>	<hr/>
Tax at the statutory tax rate of 25%	280	240
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:		
Prior year tax losses not recognised now recouped	-	(125)
	<hr/>	<hr/>
Income tax expense	280	115
	<hr/>	<hr/>

The income tax expense is recognised based on the best estimate of the weighted average annual income tax rate. The estimate takes into account the unutilised tax losses and anticipated tax payable.

**Note 7. Earnings per share**

	<b>Consolidated</b>	
	<b>31 Dec</b>	<b>31 Dec</b>
	<b>2024</b>	<b>2023</b>
	<b>\$'000</b>	<b>\$'000</b>
Profit after income tax attributable to the owners of Cryosite Limited	<u>838</u>	<u>846</u>
	<b>Number</b>	<b>Number</b>
Weighted average number of ordinary shares used in calculating basic earnings per share	<u>48,809,563</u>	<u>48,809,563</u>
Weighted average number of ordinary shares used in calculating diluted earnings per share	<u>48,809,563</u>	<u>48,809,563</u>
	<b>Cents</b>	<b>Cents</b>
Basic earnings per share	1.72	1.73
Diluted earnings per share	1.72	1.73

There have been no other transactions involving ordinary shares or potential ordinary shares since the reporting date and before completion of these financial statements.

## Note 8. Cash and cash equivalents

	Consolidated 31 Dec 2024 \$'000	30 Jun 2024 \$'000
<i>Current assets</i>		
Cash at bank and on hand	987	703
Short-term deposits	3,500	4,000
	<u>4,487</u>	<u>4,703</u>

Cash at bank and on hand earns interest at floating rates based on daily bank deposit rates. Short-term deposit is made for varying periods of between one day and six months depending on the immediate cash requirements of the Group and earn interest at the respective short-term deposit rates.

## Note 9. Trade and other receivables

	Consolidated 31 Dec 2024 \$'000	30 Jun 2024 \$'000
<i>Current assets</i>		
Trade receivables	1,776	1,441
Accrued receivables	111	30
Less: Allowance for expected credit losses	(93)	(110)
	<u>1,794</u>	<u>1,361</u>
Other receivables	51	45
	<u>1,845</u>	<u>1,406</u>

## Note 10. Customer acquisition and fulfilment costs

	Consolidated 31 Dec 2024 \$'000	30 Jun 2024 \$'000
<i>Current assets</i>		
Deferred costs - cord blood	1,082	1,126
<i>Non-current assets</i>		
Deferred costs - cord blood	6,511	7,030
	<u>7,593</u>	<u>8,156</u>
<i>Reconciliation of historical deferred cost cord blood</i>		
Opening balance	8,156	9,351
Recognised in the current year	(563)	(1,195)
Closing balance	<u>7,593</u>	<u>8,156</u>

Deferred costs represent upfront costs, such as laboratory fees, attributable for the collection and processing of cord blood and tissue samples.

**Note 11. Property, plant and equipment**

	<b>Consolidated</b>	
	<b>31 Dec</b>	<b>30 Jun</b>
	<b>2024</b>	<b>2024</b>
	<b>\$'000</b>	<b>\$'000</b>
<i>Non-current assets</i>		
Leasehold improvements - at cost	149	149
Less: Accumulated depreciation	(111)	(97)
	<u>38</u>	<u>52</u>
Fixtures and fittings - at cost	156	156
Less: Accumulated depreciation	(127)	(123)
	<u>29</u>	<u>33</u>
Information technology - at cost	269	263
Less: Accumulated depreciation	(226)	(202)
	<u>43</u>	<u>61</u>
Office furniture and equipment - at cost	68	68
Less: Accumulated depreciation	(39)	(33)
	<u>29</u>	<u>35</u>
Warehouse equipment - at cost	4,293	4,203
Less: Accumulated depreciation	(3,357)	(3,129)
	<u>936</u>	<u>1,074</u>
Tangible assets under construction - at cost	<u>410</u>	<u>196</u>
	<u><u>1,485</u></u>	<u><u>1,451</u></u>

*Reconciliations*

Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below:

	Leasehold improvements	Fixtures and fittings	Information technology	Office furniture and equipment	Warehouse equipment	Tangible assets under construction - at cost	Total
<b>Consolidated</b>	<b>\$'000</b>	<b>\$'000</b>	<b>\$'000</b>	<b>\$'000</b>	<b>\$'000</b>	<b>\$'000</b>	<b>\$'000</b>
Balance at 1 July 2024	52	33	61	35	1,074	196	1,451
Additions	-	-	9	-	90	214	313
Depreciation expense	(14)	(4)	(27)	(6)	(228)	-	(279)
Balance at 31 December 2024	<u><u>38</u></u>	<u><u>29</u></u>	<u><u>43</u></u>	<u><u>29</u></u>	<u><u>936</u></u>	<u><u>410</u></u>	<u><u>1,485</u></u>

## Note 12. Right-of-use assets

	Consolidated 31 Dec 2024 \$'000	30 Jun 2024 \$'000
<i>Non-current assets</i>		
Land and buildings - right-of-use	3,430	3,430
Less: Accumulated depreciation	(1,301)	(1,171)
	<u>2,129</u>	<u>2,259</u>

The Group leases land and buildings for its offices and warehouses under an agreement for 5 years to 30 June 2028, with the option to extend the lease by 5 years to 30 June 2033.

### Reconciliations

Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below:

Consolidated	Land and buildings \$'000
Balance at 1 July 2024	2,259
Depreciation expense	(130)
Balance at 31 December 2024	<u>2,129</u>

## Note 13. Other liabilities

	Consolidated 31 Dec 2024 \$'000	30 Jun 2024 \$'000
<i>Current liabilities</i>		
Other liabilities	64	64
<i>Non-current liabilities</i>		
Other liabilities	295	295
	<u>359</u>	<u>359</u>

As at 31 December 2024, an amount of \$359,000 remains payable to the Australian Competition and Consumer Commission ('ACCC') under the deferred settlement arrangement that commenced in 2019. An amount of \$85,000 is payable per year, with the final payment due in 2029.

#### **Note 14. Issued capital**

	<b>31 Dec 2024 Shares</b>	<b>Consolidated 30 Jun 2024 Shares</b>	<b>31 Dec 2024 \$'000</b>	<b>30 Jun 2024 \$'000</b>
Ordinary shares - fully paid	<u>48,809,563</u>	<u>48,809,563</u>	<u>3,538</u>	<u>3,538</u>

##### *Ordinary shares*

Ordinary shares entitle the holder to participate in any dividends declared and any proceeds attributable to shareholders should the Company be wound up, in proportions that consider both the number of shares held and the extent to which those shares are paid up. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

##### *Share buy-back*

There is no current on-market share buy-back.

#### **Note 15. Dividends**

##### *Dividends*

Dividends paid during the financial half-year were as follows:

	<b>Consolidated 31 Dec 2024 \$'000</b>	<b>31 Dec 2023 \$'000</b>
Final unfranked dividend paid during the half-year for the year ended 30 June 2024 of 2.0 cents (30 June 2023: 1.5 cents) per ordinary share.	<u>976</u>	<u>732</u>

#### **Note 16. Fair value measurement**

##### *Fair value hierarchy*

The following tables detail the Group's assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3: Unobservable inputs for the asset or liability

The carrying amounts of trade and other receivables and trade and other payables are assumed to approximate their fair values due to their short-term nature.

#### **Note 17. Contingent liabilities**

Bank guarantees of \$198,000 (30 June 2024: \$198,000) exist at year-end in respect of the Group's obligations under the premises lease arrangements.

**Note 18. Commitments**

Consolidated	
31 Dec	30 Jun
2024	2024
\$'000	\$'000

*Capital commitments*

Committed at the reporting date but not recognised as liabilities, payable:  
Property, plant and equipment

14	-
----	---

**Note 19. Events after the reporting period**

No matter or circumstance has arisen since 31 December 2024 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the Group's financial position as at 31 December 2024 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors

A handwritten signature in black ink, appearing to read "Mark Kerr", is written over a horizontal line.

Mark Kerr  
Non-Executive Chairman

20 February 2025

## Independent Auditor's Review Report to the Members of Cryosite Limited

### **Conclusion**

We have reviewed the accompanying half-year financial report of Cryosite Limited and its controlled entity (the "Group"), which comprises the consolidated statement of financial position as at 31 December 2024 and consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year ended on that date, significant accounting policies, explanatory notes and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Cryosite Limited and its controlled entity is not in accordance with *the Corporations Act 2001*, including:

- (i) giving a true and fair view of the Group's financial position as at 31 December 2024 and of its performance for the half-year ended on that date; and
- (ii) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

### **Other matter**

The prior year financial statements of the Group were reviewed by another auditor who expressed an unmodified conclusion. As part of our review, we have undertaken procedures considered necessary to satisfy ourselves regarding the veracity of opening consolidated balances and consolidated comparative information presented in these reports.

### **Basis for conclusion**

We conducted our review in accordance with *ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity (ASRE 2410)*. Our responsibilities are further described in the Auditor's responsibilities for the review of the half-year financial report section of our report.

We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional & Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants* (including Independence Standards) (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

### **Directors' responsibility for the half-year financial report**

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors' determine is necessary to enable the presentation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

### **Auditor's Responsibility**

Our responsibility is to express a conclusion on the half-year financial report based on our review. *ASRE 2410* requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2024 and of its performance for the half-year ended on that date, and complying with Accounting Standard *AASB 134 Interim Financial Reporting and the Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**Forvis Mazars**

**Forvis Mazars Audit & Assurance Pty Ltd**

*A. Aupied*

**Alexis Aupied**  
Director

20 February 2025

## Principal Services

1. Clinical Trials Logistics & Distribution
2. Biological Storage
3. Cell & Gene Therapies Depot Services

## Specialising In:

- GMP Temperature-Controlled Storage
- Investigational Medicinal Product (IMP) Status Management
- Date Extension Labelling for IMP unregistered goods
- GMP Secondary Packaging
- Scheduled Drug Distribution (Schedule 8 drugs)
- Destruction Services including certificates
- Reverse Logistics/Returns Management from clinical sites and hospitals
- Import and Export Services
- Validated Transport Solutions
- Long-Term Storage Options
- Legacy Cord Blood and Tissue Storage

[www.cryosite.com](http://www.cryosite.com)

TGA Licence Number MI-18072008-LI-002488-11